Navigation Links
Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO

E-1.

TIME-2 is a Phase 2/3 trial in patients with relapsed-refractory multiple myeloma. The multi-site, open-label trial will be conducted primarily in the US and Europe. TIME-2 will compare three different dose groups of tanespimycin each in combination with bortezomib. Eligible patients must have failed three prior multiple myeloma regimens, including one each of bortezomib and lenalidomide (Revlimid(R)). The primary endpoint is objective response rate.

TIME-1 is a Phase 3 trial in patients with disease relapse following a single prior course of treatment (first-relapse). It is a randomized, open- label, multi-center international trial with a primary endpoint of progression free survival (PFS). The trial will compare two groups: patients treated with bortezomib plus tanespimycin and patients treated with bortezomib alone.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors.
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference

Post Your Comments:
(Date:11/20/2009)...PHIS, Tenn., Nov. 20 S...ision is pleased to announce the signing of a tech... Department of Defense that may lead to the creati...utionize the treatment of the limbs of soldiers wh...he Defense Advanced Research Projects Agency (DARP...
(Date:11/19/2009)...BIRMINGHAM, Ala., Nov. 19 /PRNewswire-FirstCall/ -...today announced the pricing of a public offering o...r share, resulting in gross proceeds of $48.75 mil...ryst pursuant to an effective shelf registration s...Exchange Commission. BioCryst has also granted th...
(Date:11/19/2009)... TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/ -- S...rmaceutical ingredients (APIs), announced that its...Safety Certification from,SafeBridge(R) Consultant...mpetency and proficiency in the safe handling of p...d applies to specific laboratories and,production ...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Congress Appeals to Obama Administration Thailand 3A Stop Hmong Returns to Laos 49312 1Congress Appeals to Obama Administration Thailand 3A Stop Hmong Returns to Laos 49312 2NIST discovers how strain at grain boundaries suppresses high temperature superconductivity 12683 1NIST discovers how strain at grain boundaries suppresses high temperature superconductivity 12683 2Epilepsy Services on the Chopping Block 49309 1Epilepsy Services on the Chopping Block 49309 2
... Both in the Short and Long Term ...aZeneca (NYSE:,AZN) today announced new study data...-Release Tablets for the treatment of major depres...er (GAD) in adult patients.,The results from the s...eting of the American Psychiatric Association (APA...
...eep children,healthy, they also lead to more produ...save more money, according to Dr. David E. Bloom, ...Health., Bloom, who has studied the economic impa... the keynote speaker at the 11th Annual Conference...ndation for Infectious,Diseases (NFID). The confer...
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 2Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 3Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 4Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 5Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 6
(Date:11/23/2009)... The #1 Luxury Auction Company, E... Mansion in the exclusive community of Cherry Hill...r 3, 2009. , Denver, Col...uxurious home of Barbara Fentress, located in Cher...ediately and keenly aware that no details were ove...
(Date:11/22/2009)...ein known to stimulate blood vessel growth has now...wth in the development of polyps that characterize...y by Johns Hopkins researchers suggests. The findi...vel therapies to treat this form of the disease, w... Chronic sinusitis, a constant irritation and swel...
(Date:11/22/2009)...INGTON, D.C. November 18, 2009 -- When people have...tes, which enter the body from the saliva of a mos...to red blood cells. Inside the blood cells, the pa...e proteins on the cell surface that change the phy...Experiments show that infected red blood cells are...
(Date:11/22/2009)... HealthSmart, an innovative healt...hat it has successfully completed a recapitalizati...’s other lenders. Silver Point Capital, L.P... Connecticut. This recapitalization allows the Co...iness strategy. , , (PRW...
(Date:11/21/2009)..., WASHINGTON, Nov. 21 ...ment after the Senate voted to begin full debate o...o: http://www.newscom.com/cgi-bin/prnh/20080519/D...istoric step on the road to enacting health insura...le, senators will now have an opportunity to debat...
Breaking Medicine News(10 mins):Health News:Barbara Fentress, Designer of the Denver International Airport and Convention Center, Offers Her Private Mansion at Absolute Auction 2Health News:Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 2Health News:Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 3Health News:Measuring and modeling blood flow in malaria 2Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2
...k of knowledge of health risks posed by long-term...) -- As cell phone technology and use continues to...s known about the potential health risks associate...subject to high occupational exposure -- the repor...
...Researchers at the University of Pennsylvania Scho...hemical cargo in nerve cells react differently whe...tant role in Alzheimers disease. , Dynein and ki...d bump to regulate protein traffic, the group foun...
... How to Safely Enhance Athletic Performance, LAKE...e,for athletes, coaches, trainers and parents, the...ement.com ) aims to provide individuals with infor... Informed-Choice LLC, a,not-for-profit partnership...
...an. 17 Following is a,media statement attributabl... New Jersey Hospital Association:, "NJHA applauds...t,Safety Initiative report. This is a valuable doc...ement efforts. The confidential reporting and,coll...
...nwide Campaign Challenging U.S. to Close the Gaps ...al, COLUMBUS, Ohio, Jan. 17 On Tuesday, January ...Cure will host two events to,launch Ohio,s partici...an others., (Logo: http://www.newscom.com/cgi-bi...
...Jan. 17 Immunosyn,Corporation (OTC Bulletin Board...formal "Proof of Concept Trial" for the biopharmac... Europe for treatment of Diabetic Ulcers., The Bo...rtner and largest shareholder. Argyll Biotechnolog...
Other Medicine News:Health News:Report Urges More Research Into Cell Phones 2Health News:Report Urges More Research Into Cell Phones 3Health News:Alzheimer's molecule is a smart speed bump on the nerve-cell transport highway 2Health News:New Blog Provides Forum for Discussions on Supplement Safety 2Health News:Susan G. Komen for the Cure, U.S. Congressman Pat Tiberi, Ohio Senator Tom Niehaus, and OhioHealth Riverside Breast Health Center Call for Action on Breast Cancer 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 2Health News:Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019 3
Alpina Total Knee Prosthesis
...The UC-Plus Solution knee is the state of the art ...cement. Geometry of the articular surfaces does no...natomical variations, and achieves a wide area of ... Large, uninterrupted pockets of cement create a h...
RT-Plus Solution
Total Condylar Knee System
Medicine Products: